These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37398307)

  • 1. Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice.
    Ullah I; Escudie F; Scandale I; Gilani Z; Gendron-Lepage G; Gaudette F; Mowbray C; Fraisse L; Bazin R; Finzi A; Mothes W; Kumar P; Chatelain E; Uchil PD
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.
    Ullah I; Escudie F; Scandale I; Gilani Z; Gendron-Lepage G; Gaudette F; Mowbray C; Fraisse L; Bazin R; Finzi A; Mothes W; Kumar P; Chatelain E; Uchil PD
    iScience; 2024 Mar; 27(3):109049. PubMed ID: 38361624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
    Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
    Yan D; Yan B
    Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.
    Penrice-Randal R; Bentley EG; Sharma P; Kirby A; Donovan-Banfield I; Kipar A; Mega DF; Bramwell C; Sharp J; Owen A; Hiscox JA; Stewart JP
    bioRxiv; 2024 Jun; ():. PubMed ID: 38464327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.
    Wong TY; Horspool AM; Russ BP; Ye C; Lee KS; Winters MT; Bevere JR; Miller OA; Rader NA; Cooper M; Kieffer T; Sourimant J; Greninger AL; Plemper RK; Denvir J; Cyphert HA; Barbier M; Torrelles JB; Martinez I; Martinez-Sobrido L; Damron FH
    J Virol; 2022 Mar; 96(6):e0218421. PubMed ID: 35080423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
    McNamara RP; Maron JS; Boucau J; Roy V; Webb NE; Bertera HL; Barczak AK; Positives Study Staff T; Franko N; Logue JK; Kemp M; Li JZ; Zhou L; Hsieh CL; McLellan JS; Siedner MJ; Seaman MS; Lemieux JE; Chu HY; Alter G
    mBio; 2023 Aug; 14(4):e0090223. PubMed ID: 37535402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.